ERS International Congress 2022: highlights from the Respiratory Clinical Care and Physiology Assembly.

It is a challenge to keep abreast of all the clinical and scientific advances in the field of respiratory medicine. This article contains an overview of the laboratory-based science, clinical trials and qualitative research that were presented during the 2022 European Respiratory Society International Congress within the sessions from the five groups of Assembly 1 (Respiratory Clinical Care and Physiology). Selected presentations are summarised from a wide range of topics: clinical problems, rehabilitation and chronic care, general practice and primary care, mobile/electronic health (m-health/e-health), clinical respiratory physiology, exercise and functional imaging.
Competing Interests: Conflict of interest: C.Y. Hui is a visitor to the University of Edinburgh and is a senior consultant in digital health at Deloitte. Her research with the University of Edinburgh is independent from and not financially supported by Deloitte. Her views in this article are her own, and not those of Deloitte. Neither she, nor Deloitte, stand to gain financially from the work reported in this publication. Conflict of interest: R.A. Evans reports grants from NIHR/UKRI/Wolfson Foundation, personal fees from AstraZeneca and Boehringer Ingelheim, and nonfinancial support from Chiesi, outside the submitted work. Conflict of interest: G. Vagheggini reports payments for lectures from Regia Congressi, Summeet Srl and Info&Med Srl, outside the submitted work; and is President of Fondazione Volterra Ricerche Onlus, outside the submitted work. Conflict of interest: C. Vicente reports personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Mylan, outside the submitted work. Conflict of interest: S. Bayat reports personal fees from Thorasys outside the submitted work. Conflict of interest: H. Pinnock reports personal fees from Teva Pharmaceuticals and Sandoz, outside the submitted work. Conflict of interest: F.M.E. Franssen reports grants and personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees and nonfinancial support from Chiesi, and personal fees from GlaxoSmithKline, outside the submitted work. Conflict of interest: I. Vogiatzis is an associate editor of this journal. Conflict of interest: T. Gille reports personal fees from Boehringer Ingelheim and Roche, and nonfinancial support from Oxyvie, LVL Medical, Vitalaire and Asten (oxygen providers), outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose.
(Copyright ©The authors 2023.)